UK and EU regulators warn of falsified Ozempic pens in wholesale channels

Health authorities in the United Kingdom and Europe warned pharmacies and distributors in October 2023 that falsified Ozempic pens were moving through wholesale channels ^[1]. German regulators later described complex, cross-border trades behind the fake product, according to reporting on the alerts ^[1].

Novo Nordisk, the company that makes Ozempic, also warned of a surge in counterfeit versions of its medicines, according to the same reporting ^[1]. Ozempic and Wegovy are brand names for semaglutide, a GLP-1 medicine; Ozempic is prescribed for type 2 diabetes and Wegovy for weight management ^[1]. Both are given as once-weekly injections from a pen device.

The warnings were directed at the wholesale layer of the drug supply chain, the businesses that buy medicines and sell them on to pharmacies, rather than at retail shelves ^[1]. Regulators told pharmacies and distributors to be alert to pens that did not arrive through normal, licensed channels ^[1].

What has not been reported is just as important as what has. The alerts did not say what the falsified pens contained, how many were found, or which countries they turned up in beyond the UK, Germany and the wider European warnings described in the reporting ^[1]. No patient injuries tied to the fake pens have been reported in those accounts ^[1]. The identities of the traders involved in the cross-border deals described by German regulators have not been disclosed ^[1].

Why it matters for patients

The practical risk these warnings describe is not about semaglutide itself but about the path a pen takes to a patient. A medicine bought through the licensed chain, from a manufacturer to a wholesaler to a pharmacy, has been checked at each step. A falsified pen has not, and there is no reason to assume it contains the drug or the strength printed on its label. The reporting does not state what the fake pens actually held ^[1].

For readers in the United States, one question stands out: whether any of the falsified product crossed into the US supply chain. That has not been reported. The October 2023 warnings came from UK and European authorities, and the German detail about cross-border trades concerns the European market ^[1]. US regulators are not named in the reporting as issuing a related alert ^[1].

A second question is whether the counterfeits involved Ozempic specifically or the broader semaglutide line. The reporting describes counterfeit versions of both Ozempic and Wegovy, and it does not separate the two by volume or by market ^[1].

Because the warnings were issued to pharmacies and distributors, the checks they call for sit with those businesses rather than with patients. Anyone with a question about a specific pen's authenticity would need to raise it with the pharmacy that dispensed it; the reporting does not describe a public verification step patients can perform themselves ^[1].

What happens next

The reporting does not include a timeline for the investigations by UK, German or other European regulators, and no follow-up findings have been announced ^[1]. Whether the falsified pens have been traced to a single source, and whether any additional batches were identified after the October 2023 warnings, has not been reported ^[1]. It is also not known whether US authorities opened a parallel inquiry, because the reporting does not mention one ^[1].

What is established is the sequence: UK and European regulators warned the wholesale trade about fake Ozempic pens in October 2023, and German regulators then described how the fake product moved across borders ^[1]. The scope of that trade, and where the pens ended up, remains undisclosed.